Artisan Partners Urges Novartis Board Shake-Up
Analysis based on 7 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026
The public activist campaign adds governance uncertainty on top of a severe share price shock for Novartis, keeping pressure on the stock and raising the risk of further board and management changes. Broader pharma and biotech sentiment may be affected as investors reassess the value of large-cap M&A pipelines and late-stage trial risk.
Artisan Partners Asset Management, a top-20 shareholder in Swiss drugmaker Novartis, publicly called for a shake-up of the company's board to improve corporate governance and oversight of acquisitions. David Samra, managing director at Artisan Partners Asset Management and founding partner of International Value Group, said successive chairmen had failed Novartis on acquisitions and urged Chairman Bristol Myers Squibb to act, saying the board needs better talent and an acquisition committee. The call follows a record share price fall this week: on Tuesday a muscle-wasting disorder drug acquired through Novartis' $12 billion takeover of U.S. firm Avidity Biosciences failed a late-stage study, sending shares down more than 10% and wiping nearly $30 billion off market value. Shares had already fallen 3% a day earlier after heart drug pelacarsen disappointed investors. Samra also cited Novartis' 2024 acquisition of German biotech MorphoSys as disappointing, noting the company wrote down the value of that deal months later. He said he did not blame CEO Shar Narasimhan, who has led Novartis since 2018, and instead questioned whether the board exercised sufficient scrutiny over deals. Samra also urged the board to overhaul Novartis' compensation structure, saying it relies too heavily on adjusted performance measures that exclude writedowns. Novartis said its financial guidance was unchanged by the recent setbacks and that it has a broad pipeline of medicines, adding it continues a disciplined and shareholder-friendly approach to capital allocation. Artisan is the first investor to publicly call for board changes, though others have voiced concerns about Novartis' M&A strategy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard